Key points from article :
A Phase I clinical trial carried out by scientists at Wake Forest University School of Medicine has shown that a treatment designed to clear senescent cells in Alzheimer’s disease is safe.
The treatment is a combination of dasatinib and quercetin, two drugs that have been shown to target senescent cells.
The trial enrolled 5 participants aged 65 and older with symptoms of early-stage Alzheimer’s disease.
The treatment was well-tolerated and there were no significant changes in brain function.
Researchers also saw evidence to suggest that the combination therapy cleared amyloid from the brain and lowered inflammation in the blood.
A larger Phase II clinical trial is now underway to test the effects of the treatment in a larger group of patients.
The findings are published in the journal Nature.
